Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G

Blood

Volumn 107, Issue 6, 2006, Pages 2234-2242

  Schiemann, Florian ^a   Grimm, Tobias Alexander ^b   Hoch, Josef ^b   Gross, Roland ^b   Lindner, Buko ^b   Petersen, Frank ^b   Bulfone Paus, Silvia ^b   Brandt, Ernst ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; CATHEPSIN G; CHYMASE; IMMUNOGLOBULIN E; INTERLEUKIN 8; SUBSTANCE P; THROMBOCYTE FACTOR 4;

ARTICLE; CELL ACTIVATION; CELL COUNT; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS LINKING; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MAST CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 33644772132     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2424     Document Type: Article

References (51)

1. Brandt E, Petersen F, Ludwig A, et al. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 2000;67:471-478.
2. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204-216.
3. Petersen F, Ludwig A, Flad HD, Brandt E. TNF-alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J Immunol. 1996;156:1954-1962.
4. Petersen F, Bock L, Flad HD, Brandt E. Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood. 1999;94:4020-4028.
5. Petersen F, Bock L, Flad HD, Brandt E. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol. 1998;161:4347-4355.
6. Petersen F, Brandt E, Lindahl U, Spillmann D. Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4. J Biol Chem. 1999;274:12376-12382.
7. Walz A, Dewald B, von Tscharner V, Baggiolini M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med. 1989;170:1745-1750.
8. Walz A, Baggiolini M. A novel cleavage product of beta-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem Biophys Res Commun. 1989;159:969-975.
9. Brandt E, Van Damme J, Flad HD. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokine. 1991;3:311-321.
10. Petersen F, Flad HD, Brandt E. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects. J Immunol. 1994;152:2467-2478.
11. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. FEBS Lett. 1994;341:187-192.
12. Ludwig A, Petersen F, Zahn S, et al. The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood. 1997;90:4588-4597.
13. Harter L, Petersen F, Flad HD, Brandt E. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2. J Immunol. 1994;153:5698-5708.
14. Car BD, Baggiolini M, Walz A. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases. Biochem J. 1991;275(pt 3):581-584.
15. Cohen AB, Stevens MD, Miller EJ, Atkinson MA, Mullenbach G. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets. Am J Physiol. 1992;263:L249-L256.
16. Walz A, Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med. 1990;171:449-454.
17. Schenk BI, Petersen F, Flad HD, Brandt E. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol. 2002;169:2602-2610.
18. Schechter NM, Irani AM, Sprows JL, et al. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. J Immunol. 1990;145:2652-2661.
19. Schwartz LB, Riedel C, Caulfield JP, Wasserman SI, Austen KF. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J Immunol. 1981;126:2071-2078.
20. Schechter NM, Fräki JE, Geesin JC, Lazarus GS. Human skin chymotryptic proteinase. Isolation and relation to cathepsin g and rat mast cell proteinase I. J Biol Chem. 1983;258:2973-2978.
21. Withers GD, Kubes P, Ibbotson G, Scott RB. Anaphylaxis-induced mesenteric vascular permeability, granulocyte adhesion, and platelet aggregates in rat. Am J Physiol. 1998;275:H274-H284.
22. Pitchford SC, Yano H, Lever R, et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol. 2003;112:109-118.
23. Cara DC, Ebbert KV, McCafferty DM. Mast cell-independent mechanisms of immediate hypersensitivity: a role for platelets. J Immunol. 2004;172:4964-4971.
24. Gresele P, Grasselli S, Todisco T, Nenci GG. Platelets and asthma. Lancet. 1985;1:347.
25. Benyon RC, Lowman MA, Church MK. Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol. 1987;138:861-867.
26. Lawrence ID, Warner JA, Cohan VL, et al. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol. 1987;139:3062-3069.
27. Kambe N, Kambe M, Kochan JP, Schwartz LB. Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood. 2001;97:2045-2052.
28. Buhring HJ, Simmons PJ, Pudney M, et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood. 1999;94:2343-2356.
29. Kambe N, Hiramatsu H, Shimonaka M, et al. Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood. 2004;103:860-867.
30. Schwartz LB, Austen KF, Wasserman SI. Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol. 1979;123:1445-1450.
31. Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate- polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166:368-379.
32. Brandt E, Petersen F, Flad HD. A novel molecular variant of the neutrophil-activating peptide NAP-2 with enhanced biological activity is truncated at the C-terminus: identification by antibodies with defined epitope specificity. Mol Immunol. 1993;30:979-991.
33. Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (ITAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol. 2002;72:183-191.
34. He SH, Chen P, Chen HQ. Modulation of enzymatic activity of human mast cell tryptase and chymase by protease inhibitors. Acta Pharmacol Sin. 2003;24:923-929.
35. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther. 1988;244:133-137.
36. Skidgel RA, Jackman HL, Erdos EG. Metabolism of substance P and bradykinin by human neutrophils. Biochem Pharmacol. 1991;41:1335-1344.
37. Irani AA, Garriga MM, Metcalfe DD, Schwartz LB. Mast cells in cutaneous mastocytosis: accumulation of the MCTC type. Clin Exp Allergy. 1990;20:53-58.
38. Petersen F, Van Damme J, Flad HD, Brandt E. Neutrophil-activating polypeptides IL-8 and NAP-2 induce identical signal transduction pathways in the regulation of lysosomal enzyme release. Lymphokine Cytokine Res. 1991;10:35-41.
39. Babina M, Guhl S, Starke A, et al. Comparative cytokine profile of human skin mast cells from two compartments - strong resemblance with monocytes at baseline but induction of IL-5 by IL-4 priming. J Leukoc Biol. 2004;75:244-252.
40. Gibbs BF, Wierecky J, Welker P, et al. Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol. 2001;10:312-320.
41. Meier HL, Heck LW, Schulman ES, MacGlashan DW Jr. Purified human mast cells and basophils release human elastase and cathepsin G by an IgE-mediated mechanism. Int Arch Allergy Appl Immunol. 1985;77:179-183.
42. Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol. 1987;138:2611-2615.
43. Duranton J, Adam C, Bieth JG. Kinetic mechanism of the inhibition of cathepsin G by alpha 1-antichymotrypsin and alpha 1-proteinase inhibitor. Biochemistry. 1998;37:11239-11245.
44. Schechter NM, Sprows JL, Schoenberger OL, et al. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem. 1989;264:21308-21315.
45. Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2002;22:1475-1481.
46. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell protease- proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J Immunol. 1992;148:2475-2482.
47. Owen CA, Campbell MA, Boukedes SS, Campbell EJ. Inducible binding of bioactive cathepsin G to the cell surface of neutrophils. A novel mechanism for mediating extracellular catalytic activity of cathepsin G. J Immunol. 1995;155:5803-5810.
48. Yang Y, Mayo KH, Daly TJ, Barry JK, La Rosa GJ. Subunit association and structural analysis of platelet basic protein and related proteins investigated by 1H NMR spectroscopy and circular dichroism. J Biol Chem. 1994;269:20110- 20118.
49. Chen MJ, Mayo KH. Human platelet factor 4 subunit association/ dissociation thermodynamics and kinetics. Biochemistry. 1991;30:6402-6411.
50. Von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005;105:924-930.
51. Nesmelova IV, Sham Y, Dudek AZ, et al. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005;280:4948-4958.